See more : Direct Selling Acquisition Corp. (DSAQ-WT) Income Statement Analysis – Financial Results
Complete financial analysis of Marrone Bio Innovations, Inc. (MBII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marrone Bio Innovations, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- Xinhua Winshare Publishing and Media Co., Ltd. (SHXWF) Income Statement Analysis – Financial Results
- PT Golden Flower Tbk (POLU.JK) Income Statement Analysis – Financial Results
- NewHold Investment Corp. II (NHIC) Income Statement Analysis – Financial Results
- Sinher Technology Inc. (4999.TW) Income Statement Analysis – Financial Results
- I.D.I. Insurance Company Ltd. (IDIN.TA) Income Statement Analysis – Financial Results
Marrone Bio Innovations, Inc. (MBII)
About Marrone Bio Innovations, Inc.
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.31M | 100.00K | 29.37M | 21.22M | 18.17M | 14.04M | 9.80M | 9.14M | 14.54M | 7.14M | 5.25M |
| Cost of Revenue | 17.06M | 40.00K | 13.26M | 10.91M | 10.53M | 9.52M | 9.26M | 9.44M | 10.74M | 4.33M | 2.17M |
| Gross Profit | 27.25M | 60.00K | 16.11M | 10.31M | 7.64M | 4.52M | 545.00K | -302.00K | 3.81M | 2.81M | 3.08M |
| Gross Profit Ratio | 61.49% | 60.00% | 54.86% | 48.60% | 42.05% | 32.19% | 5.56% | -3.31% | 26.18% | 39.31% | 58.64% |
| Research & Development | 12.08M | 30.00K | 14.03M | 10.66M | 10.82M | 9.67M | 13.50M | 19.28M | 17.81M | 12.74M | 9.41M |
| General & Administrative | 0.00 | 75.00K | 30.07M | 19.16M | 19.81M | 18.51M | 26.50M | 28.95M | 15.02M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.57M | 75.00K | 30.07M | 19.16M | 19.81M | 18.51M | 26.50M | 28.95M | 15.02M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.29M | 6.79M |
| Operating Expenses | 42.65M | 105.00K | 44.10M | 29.82M | 30.63M | 28.18M | 40.00M | 48.23M | 32.83M | 23.04M | 16.20M |
| Cost & Expenses | 59.71M | 145.00K | 57.36M | 40.72M | 41.16M | 37.70M | 49.26M | 57.67M | 43.57M | 27.37M | 18.38M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 37.00K | 51.00K | 59.00K | 49.00K | 16.00K | 22.00K |
| Interest Expense | 1.57M | 4.00K | 1.47M | 2.51M | 7.73M | 7.30M | 4.36M | 2.91M | 6.00M | 2.47M | 88.00K |
| Depreciation & Amortization | 4.57M | 3.56M | 3.15M | 1.89M | 2.04M | 2.24M | 3.51M | 2.58M | 976.00K | 613.00K | 499.00K |
| EBITDA | -10.37M | 3.51M | -32.53M | -15.82M | -21.15M | -21.53M | -35.86M | -46.17M | -21.52M | -35.72M | -12.59M |
| EBITDA Ratio | -23.41% | 3,509.00% | -110.75% | -74.53% | -116.43% | -153.35% | -365.83% | -505.37% | -147.95% | -500.21% | -239.82% |
| Operating Income | -14.94M | -17.20M | -27.99M | -19.50M | -23.00M | -23.66M | -39.46M | -48.53M | -29.03M | -23.84M | -13.12M |
| Operating Income Ratio | -33.71% | -17,195.00% | -95.27% | -91.91% | -126.58% | -168.49% | -402.58% | -531.23% | -199.58% | -333.87% | -249.93% |
| Total Other Income/Expenses | -1.57M | 17.14M | -9.19M | -709.00K | -7.93M | -7.41M | -4.27M | -3.13M | 536.00K | -14.96M | -56.00K |
| Income Before Tax | -16.51M | -53.00K | -37.18M | -20.21M | -30.93M | -31.07M | -43.73M | -51.66M | -28.49M | -38.79M | -13.18M |
| Income Before Tax Ratio | -37.26% | -53.00% | -126.56% | -95.25% | -170.23% | -221.27% | -446.16% | -565.44% | -195.89% | -543.33% | -251.00% |
| Income Tax Expense | 45.00K | 17.15M | 15.00K | 1.80M | -201.00K | -109.00K | 92.00K | -219.00K | 6.53M | -12.49M | 32.00K |
| Net Income | -16.55M | -53.00K | -37.18M | -20.21M | -30.93M | -31.07M | -43.73M | -51.66M | -28.49M | -38.79M | -13.18M |
| Net Income Ratio | -37.36% | -53.00% | -126.56% | -95.25% | -170.23% | -221.27% | -446.16% | -565.44% | -195.89% | -543.33% | -251.00% |
| EPS | -0.09 | 0.00 | -0.32 | -0.20 | -1.06 | -1.26 | -1.79 | -2.32 | -3.26 | -2.12 | -0.72 |
| EPS Diluted | -0.09 | 0.00 | -0.32 | -0.20 | -1.06 | -1.26 | -1.79 | -2.32 | -3.20 | -2.12 | -0.72 |
| Weighted Avg Shares Out | 174.83M | 148.89M | 117.98M | 101.25M | 29.24M | 24.62M | 24.47M | 22.31M | 8.73M | 18.27M | 18.27M |
| Weighted Avg Shares Out (Dil) | 174.83M | 148.89M | 117.98M | 101.25M | 29.24M | 24.62M | 24.47M | 22.31M | 8.91M | 18.27M | 18.27M |
Marrone Bio sees 1Q revenue grow 14% on improved balance sheet amid strong biological crop protection sales
Marrone Bio Innovations Issues Shareholder Letter
Marrone Bio Innovations, Inc. Reports First-Quarter 2021 Financial Results
Wall Street mixed at midday despite better than expected jobs data
Marrone Bio says its BIOSt Nematicide seed treatment product achieved outstanding climate impact score of 9.8 out of 10
BIOSt® Nematicide Seed Treatment Reduces Greenhouse Gas Emissions in Soybeans and Corn by 85%+ Compared to Conventional Pesticides
Marrone Bio Innovations to Report First Quarter 2021 Results on Thursday, May 13th at 4:30 p.m. Eastern Time
Marrone Bio Innovations joins United Nations Global Compact, kicks off ESG initiative
Marrone Bio Innovations Joins United Nations Global Compact & Launches Environmental, Social & Governance Initiative
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports